
Quarterly report 2025-Q3
added 02-21-2026
BeyondSpring Net Debt 2011-2026 | BYSI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt BeyondSpring
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -107 M | -34 M | - | - | -11.5 M | -10.8 M | -392 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -392 K | -107 M | -32.6 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Agenus
AGEN
|
-60.8 M | $ 3.27 | -1.8 % | $ 1.17 M | ||
|
Agios Pharmaceuticals
AGIO
|
-48.9 M | $ 29.33 | -2.98 % | $ 1.7 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Akebia Therapeutics
AKBA
|
-133 M | $ 1.26 | -3.44 % | $ 324 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 0.24 | 1.1 % | $ 5.73 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Aldeyra Therapeutics
ALDX
|
-129 M | $ 5.49 | 0.52 % | $ 330 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Alector
ALEC
|
-47.4 M | $ 2.26 | -7.2 % | $ 233 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Aligos Therapeutics
ALGS
|
-132 M | $ 7.02 | -0.21 % | $ 451 M | ||
|
Alkermes plc
ALKS
|
-319 M | $ 29.32 | -2.61 % | $ 4.83 B | ||
|
Allogene Therapeutics
ALLO
|
12 M | $ 2.57 | -7.73 % | $ 403 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 330.95 | -0.59 % | $ 43.4 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Altimmune
ALT
|
-35.2 M | $ 4.2 | -2.55 % | $ 298 M | ||
|
ALX Oncology Holdings
ALXO
|
-7.15 M | $ 2.11 | 0.09 % | $ 110 M | ||
|
Amgen
AMGN
|
41 B | $ 387.85 | 0.03 % | $ 209 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 20.22 | -0.05 % | $ 945 M | ||
|
Amarin Corporation plc
AMRN
|
-189 M | $ 13.62 | -1.3 % | $ 5.55 B | ||
|
AIM ImmunoTech
AIM
|
-26.2 M | $ 0.92 | 5.25 % | $ 44.2 M | ||
|
AnaptysBio
ANAB
|
-107 M | $ 54.61 | -0.8 % | $ 1.55 B | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 14.44 | 0.53 % | $ 212 M | ||
|
ANI Pharmaceuticals
ANIP
|
166 M | $ 75.31 | 1.91 % | $ 1.45 B | ||
|
Annexon
ANNX
|
-20.5 M | $ 5.38 | -3.93 % | $ 739 M | ||
|
Annovis Bio
ANVS
|
-8.07 M | $ 2.6 | -2.99 % | $ 23.5 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Apellis Pharmaceuticals
APLS
|
-311 M | $ 20.53 | -2.05 % | $ 2.59 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.78 | -0.67 % | $ 4.25 M | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Aprea Therapeutics
APRE
|
-130 M | $ 0.88 | -3.71 % | $ 3.18 M | ||
|
Aptevo Therapeutics
APVO
|
-3.28 M | $ 7.28 | -0.55 % | $ 2.01 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Aquestive Therapeutics
AQST
|
-26 M | $ 3.99 | -0.15 % | $ 346 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-208 M | $ 8.11 | -1.44 % | $ 219 M | ||
|
Ardelyx
ARDX
|
136 M | $ 6.32 | -3.54 % | $ 1.52 B | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
argenx SE
ARGX
|
-89.9 M | $ 762.51 | -0.58 % | $ 25 B |